Lattice stabilization and enhanced diffraction in human p38α crystals by protein engineering

被引:40
作者
Patel, SB
Cameron, PM
Frantz-Wattley, B
O'Neill, E
Becker, JW
Scapin, G
机构
[1] Merck Res Lab, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Lab, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2004年 / 1696卷 / 01期
关键词
surface cysteine; protein engineering; monodispersity; reproducibility; p38; alpha; lattice stabilization;
D O I
10.1016/j.bbapap.2003.09.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitogen-activated protein (MAP) kinase p38alpha is activated in response to environmental stress and cytokines, and plays a significant role in inflammatory responses. For these reasons, it is an important target for the treatment of a wide range of inflammatory and autoimmune diseases. The crystals of p38alpha that we obtained by published procedures were usually small, quite mosaic, and difficult to reproduce and thus posed a difficulty for the intensive high-resolution studies required for a structure-guided drug discovery approach. Based on crystallographic and biochemical evidences, we prepared a single point mutation of a surface cysteine (C162S) and found that it prevents aggregation and improves the homogeneity and stability of the enzyme. This mutation also facilitates the crystallization process and increases the diffracting power of p38a crystals. Surprisingly, we found that the mutation induces a change in the conformation of a nearby surface loop resulting in stronger lattice interactions, consistent with the improved crystal quality. The mutant protein, because of its improved stability and strengthened lattice interactions, thus provides a significantly improved reagent for use in structure-based drug design for this important disease target. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:67 / 73
页数:7
相关论文
共 30 条
[1]  
Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079-6468(08)70091-2
[2]   Correlation of the phosphorylation states of pp60(c-src) with tyrosine kinase activity: The intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated [J].
Boerner, RJ ;
Kassel, DB ;
Barker, SC ;
Ellis, B ;
DeLacy, P ;
Knight, WB .
BIOCHEMISTRY, 1996, 35 (29) :9519-9525
[3]   Chemical inhibitors of protein kinases [J].
Bridges, AJ .
CHEMICAL REVIEWS, 2001, 101 (08) :2541-2571
[4]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[5]   Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b [J].
Chang, CI ;
Xu, BE ;
Akella, R ;
Cobb, MH ;
Goldsmith, EJ .
MOLECULAR CELL, 2002, 9 (06) :1241-1249
[6]   Crystal contacts engineering of aspartyl-tRNA synthetase from Thermus thermophilus:: effects on crystallizability [J].
Charron, C ;
Kern, D ;
Giegé, R .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :1729-1733
[7]   Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor [J].
Davies, TG ;
Bentley, J ;
Arris, CE ;
Boyle, FT ;
Curtin, NJ ;
Endicott, JA ;
Gibson, AE ;
Golding, BT ;
Griffin, RJ ;
Hardcastle, IR ;
Jewsbury, P ;
Johnson, LN ;
Mesguiche, V ;
Newell, DR ;
Noble, MEM ;
Tucker, JA ;
Wang, L ;
Whitfield, HJ .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (10) :745-749
[8]   Newer immunosuppressive drugs - Their potential role in rheumatoid arthritis therapy [J].
Drosos, AA .
DRUGS, 2002, 62 (06) :891-907
[9]   Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity [J].
Fitzgerald, CE ;
Patel, SB ;
Becker, JW ;
Cameron, PM ;
Zaller, D ;
Pikounis, VB ;
O'Keefe, SJ ;
Scapin, G .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (09) :764-769
[10]   Escherichia coli B γ-glutamylcysteine synthetase:: modification, purification, crystallization and preliminary crystallographic analysis [J].
Hibi, T ;
Hisada, H ;
Nakatsu, T ;
Kato, H ;
Oda, J .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :316-318